Market Overview

UPDATE: Jefferies Initiates Pluristem Therapeutics at Hold on Balanced Risk/Reward

Related PSTI
Scientific Study Published in 'Stem Cells' Show Pluristem's PLX Cells Regulate the Immune System
US Stock Futures Edge Lower Ahead Of Housing Market Index

Jefferies initiated coverage on Pluristem Therapeutics (NASDAQ: PSTI) with a Hold rating and a $3.50 price target.

Jefferies analyst Eun K. Yang commented, "Positives for PSTI include (1) real unmet need/large market potential in peripheral arterial disease (PAD) and (2) proprietary stem-cell technology platform & its potential for broad applicability. Challenges are (1) yet-tobe proven clinical efficacy of PLX cells; (2) Ph2 PLX-PAD data not until ~late-2014/early-2015; (3) difficult-to-treat PAD lead indication; and (4) potential clinical/regulatory hurdles for stem-cell products."

Pluristem Therapeutics closed at $3.08 on Monday.

Latest Ratings for PSTI

Sep 2014JefferiesMaintainsHold
Sep 2013Maxim GroupUpgradesHoldBuy
Jun 2013JefferiesMaintainsHold

View More Analyst Ratings for PSTI
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Initiation Analyst Ratings


Related Articles (PSTI)

Get Benzinga's Newsletters